Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Primmune Therapeutics

Primmune Therapeutics?uq=K9LEA9hy
2017 FOUNDED
PRIVATE STATUS
Accelerator/Inc LATEST DEAL TYPE
2 INVESTORS
Description

Developer of an orally administered toll-like receptor 7 agonist designed to stimulate innate immunity in cancer immunotherapy. The company's device produce cytokines and chemokines that up-regulate general cellular response and facilitates natural killer cell activation, enabling patients to get cured of cancer.

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Primary Office
  • 3210 Merryfield Row
  • San Diego, CA 92121
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Primmune Therapeutics’s full profile, request a free trial.

Primmune Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 03-Jan-2018 00.00 Completed Startup
1. Angel (individual) 01-Oct-2017 00.00 00.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Primmune Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
JLABS Accelerator/Incubator 000 0000 000000 0
Biobrit Venture Capital Minority 000 0000 000000 0

Primmune Therapeutics Executive Team (2)

Name Title Board
Seat
Contact
Info
Paulo Rangel Co-Founder, President, Chief Executive Officer & Director
James Appleman Ph.D Co-Founder, CSO, Senior Vice President, Research & Development & Board Member

Primmune Therapeutics Board Members (3)

Name Representing Role Since Contact
Info
James Appleman Ph.D Primmune Therapeutics Co-Founder, CSO, Senior Vice President, Research & Development & Board Member 000 0000
Paulo Rangel Primmune Therapeutics Co-Founder, President, Chief Executive Officer & Director 000 0000
Todd Harris Ph.D Self Board Member 000 0000